The International Vaccine Institute, EuBiologics, and DEK Vaccines have signed a Memorandum of Understanding at Ghana’s National Vaccine Institute, forming a new partnership to support the fill and finish of EuBiologics oral cholera vaccine.
The Institute is a non-profit international organisation with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
It also developed OCV and holds the intellectual property for the vaccine, transferring the technology to manufacturers around the world, especially Developing Countries Vaccine Manufacturers.
To date, IVI has or is currently transferring OCV technology to six manufacturers, including EuBiologics in the Republic of Korea which is currently the largest producer of OCV and will be the only supplier to the global health market by the end of the year.
Through this new tripartite partnership, IVI and EuBiologics plan to transfer OCV fill and finish technology to DEK, enabling domestic production, purchase, and sales of OCV.
Additionally, the MoU outlines further collaborative activities including support for OCV clinical trials in Ghana and other African countries, sufficiently scaling up vaccine production capacity, and gaining regulatory approvals.
Dr. Kofi Nsiah-Poku, CEO of DEK Vaccines Ltd, announced that the transfer marked the beginning of a promising technological advancement and collaboration for vaccine manufacturing in Ghana and Africa.
“This is a testament to the strength of collaboration, where individuals and organisations come together to share their expertise, knowledge, and resources for the greater good,” Dr Nsiah-Poku.
Eubiologics’ Director of International Marketing Team Leader, Rachel Park, expressed optimism for the successful commercialization of the oral cholera vaccine and expansion of other vaccine partnerships.
“We are pleased to be in collaboration with DEK for the oral cholera vaccine and believe that this is a starting point,” she added.
The International Vaccine Institute Representative, Seongmin Andrea Kim, highlighted the significant impact of the DEK & EuBiologics technology transfer for OCV on the global vaccination landscape, especially in Africa.
The Food and Drugs Authority’s Chief Executive Officer, Delese Darko, assured that the initiative would ensure good manufacturing practices and regulation regimes for all parties involved.